What is happening with PBT2?, page-13

lwlinwei, I think it is a good thing because PBT2 is in the hands of microbiologists and not neurobiologists and psychologists. Now a clinical study with PBT2 is needed. ATH managers do not know enough about how to get it started. But Dr. S. Neville knows and she has begun to work to get the otitis media study started. I think that the money needed comes from the antimicrobial fund, but unfortunately, this is only my speculation. For commercialization, a clinical study is IMO the best thing to do, there are much better deals to be expected with big pharma than without a clinical study. 700 million patients with otitis media are waiting to get PBT2 to the market.
But sure, Stamler should tell also about PBT2. I would think that the PBT2 study is part of Stamler's "transformative" year 2022.